32-adrenergic receptors ((32ARs) relax airway smooth muscle causing bronchodilation. p-agonists are commonly used drugs in asthma, but the response is erratic due to regulation from genetic variation, chronic treatment, other asthma therapies, and asthmatic inflammation. This MERIT extension will continue studies with the overall goal of understanding the basis of P2AR regulation in asthma.
In Aim 1 interactions of P2AR polymorphisms, cell-type, and modulating conditions on receptor phenotype will be ascertained, with whole- gene transfections of the (32AR representing the major human haplotypes into airway cells under various clinically relevant conditions. Studies will be carried out to define haplotype-expression relationships and their mechanisms. This will lead to a comprehensive understanding of their biology, and the fundamental basis for pharmacogenomic approaches to asthma therapy. The mechanisms of P2AR desensitization /resensitization relative to airway function in asthma remain obscure.
In Aim 2 the roles of GRK-mediated phosphorylation of P2AR on airways, particularly agonist-promoted desensitization (clinically manifested as tachyphylaxis), and adapter-protein trafficking with """"""""signal remodeling"""""""" (related to adverse airway effects of chronic treatment), will be determined. Transgenic mice will be generated with targeted expression to airway smooth muscle of the human P2AR and multiple mutated (32AR lacking phosphorylation sites for the 5 GRK isoforms. Signaling is studied in airway smooth muscle cells and correlated with airway physiology studies of contraction/relaxation under various conditions.
In Aim 3 the roles of PKA- and PKC-mediated P2AR phosphorylation on airway function will be determined, examining homologous and heterologous desensitization and receptor crosstalk, processes potentially relevant to signal dampening and dysregulated smooth muscle function. Transgenic mice will be generated with targeted expression to airway smooth muscle of mutated p2AR lacking the phosphorylation sites for PKA or PKC, and studied as in Aim 2. While we know that p-agonists, corticosteroids, and asthmatic inflammation alter airway receptors, G-proteins, or sffectors (R:G:E), the rate limiting elements are unclear, and thus mechanisms of regulation, and the nterface(s) to intervene to enhance therapy, are not known.
In Aim 4, this R:G:E stoechiometry will be ascertained by genetic manipulation of the mouse genome to increase and decrease these elements in relevant bronchodilatory and contraction circuits. Signaling at the cellular level will be correlated with function to bridge the gap between these events and relevant airway physiology. Asthma remains a serious disease affecting ~15 million in the US. Treatment with p-agonists is a mainstay of therapy, but with a better fundamental understanding of the mechanisms of receptor function and regulation, outcome can be mproved, adverse effects minimized, and new therapeutic targets defined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL045967-21
Application #
8212548
Study Section
No Study Section (in-house review) (NSS)
Program Officer
Banks-Schlegel, Susan P
Project Start
1990-09-30
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
21
Fiscal Year
2012
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
An, Steven S; Liggett, Stephen B (2018) Taste and smell GPCRs in the lung: Evidence for a previously unrecognized widespread chemosensory system. Cell Signal 41:82-88
Kim, Donghwa; Cho, Soomin; Woo, Jung A et al. (2018) A CREB-mediated increase in miRNA let-7f during prolonged ?-agonist exposure: a novel mechanism of ?2-adrenergic receptor down-regulation in airway smooth muscle. FASEB J 32:3680-3688
Kim, Donghwa; Woo, Jung A; Geffken, Ezekiel et al. (2017) Coupling of Airway Smooth Muscle Bitter Taste Receptors to Intracellular Signaling and Relaxation Is via G?i1,2,3. Am J Respir Cell Mol Biol 56:762-771
Kim, Donghwa; Pauer, Susan H; Yong, Hwan M et al. (2016) ?2-Adrenergic Receptors Chaperone Trapped Bitter Taste Receptor 14 to the Cell Surface as a Heterodimer and Exert Unidirectional Desensitization of Taste Receptor Function. J Biol Chem 291:17616-28
An, Steven S; Mitzner, Wayne; Tang, Wan-Yee et al. (2016) An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma. J Allergy Clin Immunol 138:294-297.e4
Wang, Wayne C H; Pauer, Susan H; Smith, Dan'elle C et al. (2014) Targeted transgenesis identifies G?s as the bottleneck in ?2-adrenergic receptor cell signaling and physiological function in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 307:L775-80
Liggett, Stephen B (2014) Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma. Trans Am Clin Climatol Assoc 125:64-74; discussion 74-5
Robinett, Kathryn S; Koziol-White, Cynthia J; Akoluk, Arda et al. (2014) Bitter taste receptor function in asthmatic and nonasthmatic human airway smooth muscle cells. Am J Respir Cell Mol Biol 50:678-83
Liggett, Stephen B (2013) Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators. Expert Opin Ther Targets 17:721-31
An, Steven S; Wang, Wayne C H; Koziol-White, Cynthia J et al. (2012) TAS2R activation promotes airway smooth muscle relaxation despite ?(2)-adrenergic receptor tachyphylaxis. Am J Physiol Lung Cell Mol Physiol 303:L304-11

Showing the most recent 10 out of 65 publications